Navigation Links
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
Date:2/27/2009

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium -

MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral, pan-Bcl-2 inhibitor currently in double-blinded, randomized Phase II clinical trials in both prostate cancer and non-small cell lung cancer, is the lead compound in Ascenta Therapeutics' portfolio of apoptosis-triggering small molecules.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873 )

"This is the first report of several we plan to present this year from a large and growing data set demonstrating the broad therapeutic potential of AT-101," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "The evidence of resistance reversal from this refractory population supplements the earlier clinical data demonstrating robust activity with the same regimen in docetaxel-naive patients."

Initial findings from the ongoing open-label, multi-center study demonstrates that AT-101 can be administered safely with D/P in these patients. Investigators also observed clinical responses, based on both PSA and RECIST criteria, including four patients with a confirmed PR (partial response, defined as a PSA decline of 50 percent or greater).

"This first look at the data is very encouraging, particularly since all of these patients were truly refractory to docetaxel, having not simply failed to respond but actually experienced disease progression during prior therapy," said James Reeves, MD, principal investigator, Florida Cance
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
2. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... & Sullivan honors KJAYA Medical with ... Innovation Award in Web-based Medical Imaging Data Management ... For the first time, medical facilities can manage ... industry-standard applications, leading-edge 3D processing, PET/CT analysis and ...
... Nov. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Global Pipeline Analysis, Opportunity Assessment and ... http://www.reportlinker.com/p0685950/Spinal-Non-Fusion-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic ...
Cached Medicine Technology:KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 3Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 4Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 5Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 6Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 7Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 8Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 9
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- A new ... abusers from snorting or injecting the drug has been ... Called Targiniq ER and made by Purdue Pharma, the ... naloxone, a drug that blocks the euphoric effects of ... is crushed, snorted, dissolved or injected, according to the ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... 2014 ACRIA & AMIDA CARE TO COHOST ... , Save the Dates: August 7th & August 8th* ... cohost “A Dialogue for Life” forums this August, led by ... Office of National AIDS Policy (ONAP). This will be a ... locally by AIDS organizations, consumers and advocates to advance the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 National Analysts ... announced that it will operate globally under the name, ... remains a woman-owned Employee Stock Ownership Plan (ESOP) organization ... Schwartz McDonald, Ph.D . The firm guides market ... powerful analytics. , Said McDonald, “We wanted our ...
(Date:7/24/2014)... July 24, 2014 For the first time in ... United States. The Scottish singer first became a known musical commodity ... Her first song on the show was “I Dreamed a Dream,” ... released five studio albums since her time on the reality show ... in front of her American fans. The tour will kick off ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... coverage with 99.99% ... captioning uptime, CANONSBURG, ... watched news reports, exit polls, and,election results for hundreds of national, ... networks and local stations,across the country, VITAC realtime captioners provided English ...
... financial advisor with,Minneapolis-based North Star Resource Group, has been ... Doctors" in 2008. The list of,top advisors will appear ... on,nominations from clients and survey data completed by advisors., ... said Dave,Vasos, co-president and chief financial officer of North ...
... The,patient-centered medical home, personal health records and emergency,department ... "Best in,Medicine" conference presented by the Michigan State Medical ... 3:30 p.m. at The Inn at St. John,s,in Plymouth., ... benefits and,cost-savings of the emerging health care model that ...
... Quarter Highlighted by Submission of NDA for Novel Antidepressant and ... Steady Global Growth for Once-Daily Tramadol - ... DDS;,NASDAQ: DDSS) today reported its results for the third quarter ... otherwise,stated., "We are very pleased with the progress of ...
... 7 EntreMed, Inc.,(Nasdaq: ENMD ) a ... cancer and inflammatory diseases,announced today that James S. ... Company update at the Rodman and Renshaw 10th ... 2008 at the New,York Palace Hotel in New ...
... same quarter in Fiscal 2008 -, (all ... BELLEVILLE, ON, Nov. 7 /PRNewswire-FirstCall/ - Bioniche ... company, today announced financial results for the first,quarter ... 2008., "Our revenues are up by 37% ...
Cached Medicine News:Health News:Flawless Captioning Service Brings Obama Victory and Speech to Deaf and Hard-Of-Hearing Viewers 2Health News:Andy Tate, North Star Resource Group Advisor, Named One of Medical Economics' '150 Best Financial Advisors for Doctors' 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference 2Health News:Bioniche Reports Fiscal 2009 First Quarter 2Health News:Bioniche Reports Fiscal 2009 First Quarter 3Health News:Bioniche Reports Fiscal 2009 First Quarter 4Health News:Bioniche Reports Fiscal 2009 First Quarter 5Health News:Bioniche Reports Fiscal 2009 First Quarter 6Health News:Bioniche Reports Fiscal 2009 First Quarter 7Health News:Bioniche Reports Fiscal 2009 First Quarter 8Health News:Bioniche Reports Fiscal 2009 First Quarter 9Health News:Bioniche Reports Fiscal 2009 First Quarter 10Health News:Bioniche Reports Fiscal 2009 First Quarter 11Health News:Bioniche Reports Fiscal 2009 First Quarter 12
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: